ENDOMETRIAL ADENOCARCINOMA
Clinical trials for ENDOMETRIAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Two drugs vs. one: new hope for Tough-to-Treat uterine cancer
Disease control Recruiting nowThis study is for people whose endometrial (uterine) cancer has returned after treatment. It compares two different immunotherapy approaches to see which is better at controlling the cancer. One group gets a single immunotherapy drug (nivolumab), while the other gets a combinatio…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New cancer drug enters human testing for Tough-to-Treat tumors
Disease control Recruiting nowThis early-stage study is testing a new drug called APL-5125 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe dose, check for side effects, and see if the drug can shrink tumors, especially in colorectal canc…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Personalized cancer drug trial seeks to control advanced uterine cancer
Disease control Recruiting nowThis study is testing whether the drug ACR-368 can help control advanced endometrial cancer that has progressed after previous treatments. The trial will enroll 353 participants and uses a personalized approach: some patients receive ACR-368 alone while others receive it with a l…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Acrivon Therapeutics • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC